BioMed

🧬 BioMed Pulse · 2026-09-28 02:01 UTC

BIOMED PULSE

Monday, September 28, 2026 — Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now spread to 61 health zones across six provinces, making it the largest Ebola outbreak ever recorded in the DRC — and it is still accelerating. ^[1]

Mood: Urgent on outbreak front; cautiously encouraging on longevity and drug development.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) — DRC AND UGANDA, ACTIVE AND ESCALATING

As of September 25, 2026, the Bundibugyo virus disease (BVD) outbreak in the DRC has expanded to two additional health zones, including Bulu health zone in a new province, Sud Ubangi, on the north-west border — raising the total affected area to 61 health zones across six of 26 provinces. ^[1]
The six affected provinces are Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo, plus the newly breached Sud Ubangi, indicating geographic spread toward Congo's northwest corridor. ^[1]
WHO designated this the largest Ebola outbreak ever reported in the DRC, characterized by sustained urban and rural transmission and a case fatality profile consistent with Bundibugyo virus (historically ~25-40%). ^[2]
As of July 15, 2026, cumulative confirmed cases stood at 2,124 with 828 deaths from DRC alone; case counts have continued climbing through subsequent WHO Disease Outbreak News reports. ^[3]
Cross-border transmission into Uganda was confirmed early in the outbreak; WHO and CDC have both mobilized emergency response operations. ^[4] ^[5]
CDC enhanced Ebola airport screening was active at Washington-Dulles International and Atlanta airports as of late May 2026, targeting travelers from affected countries. ^[6] ^[7]

HANTAVIRUS (ANDES VIRUS) — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

The Andes hantavirus (ANDV) outbreak linked to the M/V Hondius cruise ship, first reported to WHO on May 2, 2026, has produced multiple confirmed and suspected cases of severe acute respiratory illness across international travelers; the fifth WHO Disease Outbreak News report was issued July 2, 2026. ^[8]
Initial cluster involved 147 onboard passengers and crew, with laboratory-confirmed Andes hantavirus cases identified; Andes hantavirus is notable for documented person-to-person transmission unlike most hantavirus strains. ^[9] ^[10]
CDC issued multiple response transcripts through late June 2026, confirming ongoing U.S. government monitoring and extremely low risk to the general American public.

LISTERIA — PREPARED MEALS, ONGOING U.S. OUTBREAK

CDC expanded its Listeria monocytogenes outbreak alert on September 26, 2026, to include additional prepared meal products, with 3 new illnesses and 1 additional death reported in the latest update.
Consumers are urged to check refrigerators and freezers for all recalled prepared food products and discard them immediately.

DRUG-RESISTANT BACTERIA — SHARP NATIONAL RISE

A CDC report released September 23, 2026 found a dramatic increase in dangerous drug-resistant bacteria, raising concern for clinical treatment failure across multiple pathogen classes.

CONGENITAL SYPHILIS — 12TH CONSECUTIVE YEAR OF INCREASE

New CDC data published September 24, 2026 show U.S. congenital syphilis cases rose for the 12th consecutive year in 2024, signaling continued failure to intercept maternal syphilis before delivery.

ANIMAL RABIES — ELEVATED HUMAN EXPOSURE RISK

CDC issued a statement September 10, 2026 flagging a notable increase in animal rabies activity and associated human exposure incidents across the United States.

CANCER MORTALITY — ENCOURAGING SIGNAL

CDC's Annual Report to the Nation, released September 22, 2026, credits progress against lung cancer as a primary driver of declining overall U.S. cancer mortality.

🧬 LONGEVITY & AGING

SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP) — NEW MEASUREMENT TOOLS

Researchers published a methods paper characterizing the SASP — the cocktail of inflammatory signals that senescent cells emit and that drives many aging-related diseases — in both primary and induced pluripotent stem cell-derived skin cells, using multiplex assays that allow simultaneous measurement of many SASP factors at once.
This toolkit is significant because reliably quantifying SASP has been a bottleneck in testing senolytics (drugs that kill senescent cells) and senomorphics (drugs that suppress SASP output).

RADIATION-INDUCED CELLULAR SENESCENCE — HAIR FOLLICLE AND BONE

Ionizing radiation triggers senescence in dermal papilla cells (the stem-cell-containing structures at the base of hair follicles) by suppressing the FOXM1-KIF20A molecular pathway, according to new research published in Genes & Disease — linking radiation exposure directly to hair aging and loss.
A separate study found that molecular hydrogen may act as a radioprotective agent against environmental radiation damage, potentially scavenging hydroxyl free radicals before they can damage DNA or trigger senescent signaling.
A dual-targeting mRNA lipid nanoparticle system was shown to restore ABCA1-dependent cholesterol homeostasis in aging bone cells, promoting repair of age-related bone defects in preclinical models — an intersection of gene-delivery technology and skeletal aging biology.

FRAILTY AND INFLUENZA VACCINATION — THE FRAILTY PARADOX

A study published in Lancet Healthy Longevity identified what researchers call the frailty-influenza paradox: frail older adults face dramatically higher risk of severe influenza infection, yet they show greater benefit from high-dose compared to standard-dose influenza vaccine.
The DANFLU-2 randomized trial prespecified analysis confirmed that high-dose influenza vaccine significantly reduces hospitalization risk in frail older adults compared with the standard dose, strengthening the case for dose-stratified vaccination protocols in care settings.

HIP FRACTURE SURGERY AND ANESTHESIA TYPE IN OLDER PATIENTS

A multicenter German randomized clinical trial published in Lancet Healthy Longevity compared spinal versus general anaesthesia in older hip fracture patients and assessed rates of serious complications — a question with direct implications for frailty and perioperative longevity.
An accompanying editorial asks whether this study is definitive enough to settle the long-running clinical debate over anesthesia choice in this high-mortality patient population.

UROLITHIN A AND GLUCOSE METABOLISM IN OLDER ADULTS

A randomized triple-masked controlled clinical trial (NCT06274749) is actively investigating whether urolithin A (UA) supplementation — a gut-microbiome-derived compound that activates mitophagy, the cellular recycling of damaged mitochondria — can improve glucose metabolism and insulin secretion in healthy adults aged 55 and older.
Pancreatic beta-cell function declines with age, contributing to rising blood glucose and type 2 diabetes risk; UA's mitophagy-activation mechanism makes it a candidate for slowing this specific aging process.

DEPRESCRIBING IN OLDER ADULTS — FRAMEWORK DEBATE

Two commentaries published in Lancet Healthy Longevity argue that clinical trials testing medication removal (deprescribing) in older adults must establish a mechanistic rationale before selecting a trial design — a methodological point with major implications for reducing polypharmacy-related harm in aging populations.

FRAILTY AND PHYSICAL RESERVE — NEW TRIAL

A clinical trial (NCT07513701) registered September 25, 2026, aims to test combined aerobic and resistance training in physically frail older adults to enhance physical reserve and preserve both cognitive and physical function over time.

OSTEOARTHRITIS AND EXTRACELLULAR VESICLES

A review in Bioactive Materials describes how extracellular vesicles — nano-scale membrane particles shed by cells — play context-dependent roles in osteoarthritis, acting as disease drivers in some microenvironments and as repair promoters in others, with implications for joint aging therapies.

ATHEROSCLEROSIS — SINGLE-CELL-GUIDED DRUG DISCOVERY

Single-cell sequencing analysis identified narciclasine as a dual inhibitor of VCAM-1 and ICAM-1, two adhesion molecules that drive inflammatory plaque formation in atherosclerosis — a disease whose prevalence rises sharply with age.

💊 NEW CURES & APPROVALS

INLURIYO (IMLUNESTRANT TOSYLATE) — ELI LILLY AND CO, SUPPLEMENTAL APPROVAL

Eli Lilly received a supplemental FDA approval (NDA218881) for Inluriyo (imlunestrant tosylate), an oral selective estrogen receptor degrader (SERD) targeting estrogen-receptor-positive breast cancer.

VERZENIO (ABEMACICLIB) — ELI LILLY AND CO, SUPPLEMENTAL APPROVAL

Eli Lilly also received a supplemental approval (NDA208716) for Verzenio (abemaciclib), a CDK4/6 inhibitor used in hormone receptor-positive, HER2-negative breast cancer, potentially covering a new indication or patient subgroup.

WINREVAIR (SOTATERCEPT-CSRK) — MERCK SHARP DOHME, SUPPLEMENTAL APPROVAL

Merck Sharp Dohme received a supplemental FDA approval (BLA761363) for Winrevair (sotatercept-csrk), an activin signaling inhibitor for pulmonary arterial hypertension, a disease characterized by progressive vascular remodeling.

NUBEQA (DAROLUTAMIDE) — BAYER HEALTHCARE, SUPPLEMENTAL APPROVAL

Bayer Healthcare received a supplemental FDA approval (NDA212099) for Nubeqa (darolutamide), an androgen receptor inhibitor used in prostate cancer treatment.

SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — NOVARTIS, SUPPLEMENTAL APPROVAL

Novartis received a supplemental FDA approval (NDA215358) for Scemblix (asciminib hydrochloride), a STAMP inhibitor (specifically targeting the ABL myristoyl pocket) used in chronic myeloid leukemia (CML), potentially expanding eligible patient populations.

SOHONOS (PALOVAROTENE) — IPSEN, SUPPLEMENTAL APPROVAL

Ipsen received a supplemental FDA approval (NDA215559) for Sohonos (palovarotene), a retinoic acid receptor gamma agonist used in fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder causing abnormal bone formation.

AQNEURSA (LEVACETYLLEUCINE) — INTRABIO, SUPPLEMENTAL APPROVAL

IntraBio received a supplemental FDA approval (NDA219132) for AQNEURSA (levacetylleucine) for a neurological indication, with levacetylleucine acting as a modified amino acid targeting lysosomal storage disorders.

DEFLAZACORT — HIKMA, NEW GENERIC APPROVAL

Hikma received an original ANDA (ANDA220524) approval for generic deflazacort, a corticosteroid used in Duchenne muscular dystrophy.

LANREOTIDE ACETATE — AMNEAL, NEW GENERIC APPROVAL

Amneal received an original ANDA (ANDA218217) for generic lanreotide acetate, a somatostatin analogue used in acromegaly and neuroendocrine tumors.

🧪 CLINICAL TRIALS

TRONTINEMAB FOR EARLY ALZHEIMER'S DISEASE — PHASE TRIAL REGISTERED

A new clinical trial (NCT07170150, registered September 25, 2026) is evaluating the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease, covering the spectrum from mild cognitive impairment (MCI) through mild dementia; trontinemab is a brain-penetrant anti-amyloid antibody designed to more efficiently cross the blood-brain barrier than prior generation agents.

UROLITHIN A FOR GLUCOSE METABOLISM IN ADULTS 55+ — ACTIVE RCT

Trial NCT06274749 (registered and active, updated September 25, 2026) is a randomized triple-masked controlled study testing urolithin A supplementation's effect on pancreatic beta-cell function and glucose control in adults aged 55 and older, targeting the mitophagy pathway.

FRAILTY AND EXERCISE INTERVENTION — NCT07513701

Trial NCT07513701 tests combined aerobic and resistance training in physically frail older adults to build physical reserve and protect against cognitive and functional decline; registered September 25, 2026.

BPL-1357 UNIVERSAL INFLUENZA CHALLENGE STUDY — NCT07215858

Trial NCT07215858 (September 25, 2026) is testing BPL-1357, a broad-spectrum influenza candidate vaccine, against live H1N1 challenge in healthy volunteers, with the goal of informing pandemic preparedness against novel influenza strains.

VIRTUAL LIFE STORY CLUB FOR LONELINESS IN OLDER ADULTS — NCT06919094

Trial NCT06919094 (September 25, 2026) is testing a virtual group reminiscence therapy intervention to reduce loneliness and apathy in community-dwelling older adults, combining structured social engagement with personal narrative recall, a non-pharmacological geroscience approach.

VELOCITY-LOSS RESISTANCE TRAINING IN PARKINSON'S DISEASE — NCT07840508

Trial NCT07840508 (September 25, 2026) is comparing resistance training at 10% versus 30% velocity-loss thresholds in older adults with Parkinson's disease, measuring effects on muscle strength, power, and daily function.

📢 PUBLIC HEALTH

LISTERIA RECALL — CHECK YOUR PREPARED MEALS NOW

CDC continues to warn consumers that Listeria-contaminated prepared meal products remain in homes despite ongoing recalls; 3 additional illnesses and 1 additional death were added to the outbreak count as of September 26, 2026, and new product categories were added to the recall list.

DRUG-RESISTANT BACTERIA ON THE RISE

CDC's new September 2026 report on antimicrobial resistance found a sharp rise in dangerous drug-resistant bacterial infections — a finding that underscores the need for antibiotic stewardship and new therapeutic development.

CONGENITAL SYPHILIS — 12 CONSECUTIVE YEARS OF INCREASES

New 2024 surveillance data confirm congenital syphilis has risen for 12 straight years; CDC urges prenatal syphilis screening and treatment as the most effective intervention.

CANCER MORTALITY DECLINING — LUNG CANCER PROGRESS KEY DRIVER

The 2026 Annual Report to the Nation shows overall U.S. cancer death rates are declining, with lung cancer improvements — driven by reduced smoking rates and better treatment — leading the way.

RABIES EXPOSURE ALERT — ANIMAL ACTIVITY ELEVATED

CDC flagged increased animal rabies activity and a rise in human exposures across the U.S. as of September 10, 2026; people bitten or scratched by wild animals should seek immediate post-exposure prophylaxis.

NOTE: This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal medical decisions.

📎 Sources

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260928-02-v89 · 2026-09-28 02:01 UTC · pulse.uzylab.com

🧬 BioMed Pulse · 2026-09-28 02:01 UTC

⚡ TL;DR

🦠 OUTBREAKS & VIRUSES

🧬 LONGEVITY & AGING

💊 NEW CURES & APPROVALS

🧪 CLINICAL TRIALS

📢 PUBLIC HEALTH

📎 Sources

Read next

BioMed Pulse · 2026-10-04 02:01 UTC

BioMed Pulse · 2026-10-03 02:01 UTC

BioMed Pulse · 2026-10-02 02:01 UTC